Market Cap ₹128 Cr.
Stock P/E 36.2
P/B 2.2
Current Price ₹61.5
Book Value ₹ 28.6
Face Value 10
52W High ₹110.9
Dividend Yield 0.81%
52W Low ₹ 44.1
Lotus Eye Hospital and Institute Ltd is a leading healthcare organization dedicated to advanced eye care solutions. Established with a vision to provide world-class ophthalmic services, the company offers a comprehensive range of treatments for various eye conditions. With state-of-the-art facilities and cutting-edge technology, Lotus Eye Hospital specializes in cataract surgery, refractive surgeries like LASIK, corneal transplantation, glaucoma management, and retina treatments. Their team of highly skilled ophthalmologists and support staff is committed to delivering exceptional patient care and promoting eye health. As a trusted name in the field of eye care, Lotus Eye Hospital and Institute Ltd strives to improve vision and enhance the quality of life for patients through excellence, compassion, and innovation.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 11 | 12 | 11 | 12 | 12 | 12 | 11 | 13 | 13 | 12 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 11 | 12 | 11 | 12 | 12 | 12 | 12 | 13 | 13 | 12 |
| Total Expenditure | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 10 |
| Operating Profit | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | -0 | 0 | -0 | 0 | -0 | 0 | -0 | 0 | 0 | -0 |
| Profit Before Tax | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 1 |
| Provision for Tax | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Profit After Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Adjustments | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Adjusted Earnings Per Share | 0.6 | 0.7 | 0.3 | 0.7 | 0.4 | 0.6 | 0.3 | 0.7 | 0.4 | 0.3 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 29 | 29 | 30 | 31 | 34 | 38 | 38 | 41 | 32 | 39 | 47 | 49 |
| Other Income | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total Income | 30 | 29 | 30 | 32 | 35 | 39 | 39 | 41 | 33 | 40 | 48 | 50 |
| Total Expenditure | 26 | 26 | 29 | 28 | 31 | 34 | 35 | 37 | 29 | 33 | 39 | 41 |
| Operating Profit | 4 | 3 | 2 | 4 | 4 | 5 | 4 | 5 | 4 | 7 | 9 | 9 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -0 | 0 | -0 | -1 | 0 | -0 | -0 | 0 |
| Profit Before Tax | 0 | 0 | -2 | -0 | 0 | 2 | 1 | 1 | 2 | 4 | 6 | 5 |
| Provision for Tax | 0 | 0 | -0 | -0 | -0 | -0 | -0 | 0 | 0 | 1 | 2 | 1 |
| Profit After Tax | 0 | 0 | -2 | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 4 | 4 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | -2 | 0 | 0 | 2 | 1 | 1 | 2 | 3 | 4 | 4 |
| Adjusted Earnings Per Share | 0.2 | 0 | -1 | 0 | 0.2 | 0.8 | 0.3 | 0.5 | 0.8 | 1.4 | 2 | 1.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 21% | 5% | 4% | 5% |
| Operating Profit CAGR | 29% | 22% | 12% | 8% |
| PAT CAGR | 33% | 59% | 15% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -18% | 5% | 26% | 25% |
| ROE Average | 7% | 5% | 4% | 2% |
| ROCE Average | 10% | 8% | 6% | 3% |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 51 | 51 | 49 | 49 | 50 | 51 | 50 | 51 | 53 | 55 | 58 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | -0 | -0 | -0 | 0 | -0 | 1 | 0 |
| Total Current Liabilities | 5 | 7 | 6 | 5 | 4 | 7 | 6 | 6 | 6 | 6 | 5 |
| Total Liabilities | 57 | 59 | 56 | 55 | 55 | 57 | 56 | 57 | 58 | 61 | 63 |
| Fixed Assets | 45 | 47 | 47 | 44 | 41 | 43 | 44 | 43 | 41 | 44 | 44 |
| Other Non-Current Assets | 4 | 5 | 4 | 5 | 6 | 7 | 5 | 4 | 4 | 4 | 4 |
| Total Current Assets | 7 | 7 | 5 | 6 | 7 | 8 | 7 | 11 | 14 | 13 | 15 |
| Total Assets | 57 | 59 | 56 | 55 | 55 | 57 | 56 | 57 | 58 | 61 | 63 |
| #(Fig in Cr.) | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | -0 | 2 | 1 | 1 | 2 | 3 | 4 | 3 | 7 | 10 | 9 |
| Cash Flow from Operating Activities | 4 | 4 | 2 | 3 | 3 | 6 | 4 | 5 | 3 | 4 | 4 |
| Cash Flow from Investing Activities | -1 | -5 | -5 | -1 | -1 | -4 | -4 | -1 | 0 | -4 | -2 |
| Cash Flow from Financing Activities | -0 | -1 | 2 | -1 | -0 | -2 | -1 | 0 | -0 | -2 | -2 |
| Net Cash Inflow / Outflow | 2 | -1 | -0 | 2 | 2 | 0 | -1 | 4 | 3 | -1 | 0 |
| Closing Cash & Cash Equivalent | 2 | 1 | 1 | 2 | 3 | 4 | 3 | 7 | 10 | 9 | 9 |
| # | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0.2 | 0.02 | -0.95 | 0.05 | 0.21 | 0.84 | 0.34 | 0.51 | 0.75 | 1.44 | 1.96 |
| CEPS(Rs) | 1.73 | 1.45 | 0.94 | 1.79 | 1.87 | 2.46 | 1.81 | 1.71 | 1.87 | 2.64 | 3.39 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0.5 | 0.5 | 0 | 0 | 0.5 | 0.5 | 0.5 |
| Book NAV/Share(Rs) | 24.67 | 24.7 | 23.75 | 23.8 | 24.07 | 24.35 | 24.1 | 24.65 | 25.34 | 26.26 | 27.69 |
| Core EBITDA Margin(%) | 10.5 | 9.5 | 4.6 | 10.21 | 9.8 | 11.44 | 8.39 | 9.82 | 11.23 | 15.25 | 16.35 |
| EBIT Margin(%) | 1.74 | 0.49 | -7.05 | 0.43 | 1.67 | 4.95 | 2.19 | 4.17 | 6.58 | 11.07 | 12.45 |
| Pre Tax Margin(%) | 1.56 | 0.35 | -7.44 | -0.07 | 1.23 | 4.48 | 1.63 | 3.59 | 6.15 | 10.52 | 12.01 |
| PAT Margin (%) | 1.43 | 0.14 | -6.63 | 0.32 | 1.31 | 4.59 | 1.84 | 2.63 | 4.84 | 7.67 | 8.67 |
| Cash Profit Margin (%) | 12.38 | 10.51 | 6.56 | 11.97 | 11.44 | 13.46 | 9.8 | 8.78 | 12.04 | 14.1 | 15 |
| ROA(%) | 0.73 | 0.07 | -3.45 | 0.18 | 0.81 | 3.12 | 1.25 | 1.89 | 2.71 | 4.99 | 6.58 |
| ROE(%) | 0.81 | 0.08 | -3.93 | 0.2 | 0.89 | 3.47 | 1.41 | 2.1 | 3.02 | 5.56 | 7.27 |
| ROCE(%) | 0.99 | 0.27 | -4.14 | 0.27 | 1.13 | 3.71 | 1.66 | 3.32 | 4.07 | 8 | 10.43 |
| Receivable days | 4.33 | 4.47 | 4.56 | 5.06 | 6.41 | 8.74 | 9.03 | 6.41 | 7.9 | 6.4 | 6.97 |
| Inventory Days | 32.92 | 43.16 | 41.03 | 34.39 | 24.61 | 20.1 | 21.58 | 19.21 | 21.95 | 19.16 | 19.77 |
| Payable days | 152.54 | 150.99 | 118.72 | 117.66 | 86.95 | 108.13 | 110.55 | 87.95 | 106.98 | 96.13 | 81.76 |
| PER(x) | 37.53 | 322.34 | 0 | 329.07 | 173.07 | 33.28 | 65.07 | 45.52 | 55.57 | 37.18 | 29.62 |
| Price/Book(x) | 0.3 | 0.25 | 0.52 | 0.67 | 1.54 | 1.15 | 0.92 | 0.95 | 1.65 | 2.03 | 2.1 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 1.35 | 1.79 | 0 | 0 | 1.19 | 0.94 | 0.86 |
| EV/Net Sales(x) | 0.46 | 0.41 | 0.87 | 1.01 | 2.18 | 1.44 | 1.14 | 1.03 | 2.39 | 2.63 | 2.39 |
| EV/Core EBITDA(x) | 3.66 | 3.8 | 14.36 | 8.36 | 18.29 | 10.48 | 11.2 | 8.55 | 17.7 | 14.99 | 12.71 |
| Net Sales Growth(%) | 10.99 | -1.42 | 4.19 | 4.13 | 9.1 | 11.95 | 1.06 | 5.54 | -20.18 | 20.21 | 20.9 |
| EBIT Growth(%) | 123.15 | -72.15 | -1590.1 | 106.43 | 319.87 | 231.35 | -55.3 | 101.06 | 25.78 | 102.31 | 35.94 |
| PAT Growth(%) | 118.43 | -90.6 | -5178.97 | 105.09 | 340.48 | 293.4 | -59.47 | 50.37 | 47.29 | 90.33 | 36.63 |
| EPS Growth(%) | 118.44 | -90.58 | -5166.49 | 105.09 | 340.48 | 293.4 | -59.47 | 50.38 | 47.29 | 90.33 | 36.62 |
| Debt/Equity(x) | 0.01 | 0 | 0.02 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0 |
| Current Ratio(x) | 1.46 | 0.98 | 0.82 | 1.38 | 1.61 | 1.16 | 1.17 | 1.79 | 2.34 | 2.24 | 2.83 |
| Quick Ratio(x) | 0.84 | 0.44 | 0.31 | 0.77 | 1.18 | 0.82 | 0.79 | 1.43 | 2.03 | 1.83 | 2.3 |
| Interest Cover(x) | 9.51 | 3.4 | -17.96 | 0.87 | 3.78 | 10.39 | 3.93 | 7.13 | 15.52 | 20.09 | 28.69 |
| Total Debt/Mcap(x) | 0.02 | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | 0 | 0.01 | 0 | 0 | 0 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 57.74 | 57.74 | 57.74 | 57.88 | 58.14 | 58.17 | 58.43 | 57.58 | 56.58 | 41.4 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 42.26 | 42.26 | 42.26 | 42.12 | 41.86 | 41.83 | 41.57 | 42.42 | 43.42 | 58.6 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.2 | 1.2 | 1.2 | 1.2 | 1.21 | 1.21 | 1.22 | 1.2 | 1.18 | 0.86 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.88 | 0.88 | 0.88 | 0.88 | 0.87 | 0.87 | 0.86 | 0.88 | 0.9 | 1.22 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Sell or Purchase Share (Tentative Price)
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | GMP | Expected Listing | Listing Gain(%) | Listing Price | Current Price | Type | Exchange |
|---|
You May Also Know About
